Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyMolina Ebglyss Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedMolina HealthcarePolicy C29044-A

    Ebglyss (lebrikizumab) Coverage Criteria

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C29044-A alerts

    Get alerted when Policy C29044-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and continuation coverage for Ebglyss (lebrikizumab-lbkz) in members aged 12 years and older with moderate-to-severe atopic dermatitis, including clinical eligibility, treatment history, documentation, dosing, administration, and Illinois-specific requirements.

    Policy Summary
    PayerMolina Healthcare
    PolicyEbglyss (lebrikizumab) Coverage Criteria
    Policy CodePolicy C29044-A
    Change TypeModified
    Effective DateSep 24, 2026
    Next Review DateApr 1, 2027
    Key ActionSubmit prior authorization documentation for Ebglyss, including clinical criteria, treatment history, and qualified prescriber information.
    SourceLink
    POLICY UPDATE CHANGES

    The Q3 2026 revision history identifies quantity and reference updates.

    The Q2 2026 revision history identifies revisions to required medical information and the duration of approval.

    The Q3 2025 revision history identifies revisions to required medical information, exclusions/discontinuation, other special considerations, available dosage forms, and references.

    The policy was created with new criteria in Q1 2025.

    12+Minimum member age
    6 monthsInitial authorization
    12 monthsContinuation authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    BSA ≥10%Disease extent
    250 mg q4 or q8 weeksMaintenance dosing
    IllinoisState-specific provisions

    Coverage Criteria

    Initial Therapy

    Covered for moderate-to-severe atopic dermatitis when ALL of the following are met.

    Initial therapy

    • Diagnosis: Documented diagnosis of moderate-to-severe chronic atopic dermatitis (eczema).
    • No prohibited combination therapy: The member is not receiving concurrent treatment with, and Ebglyss will not be used in combination with, a TNF inhibitor, biologic response modifier, other biologic DMARD, Janus kinase inhibitor, or phosphodiesterase 4 inhibitor.

      Verification may be by prescriber attestation, member medication fill history, or submitted documentation.

    • Disease extent

      • Extensive involvement: Atopic dermatitis involvement is estimated at at least 10% of the body surface area according to the prescribing physician.≥10% BSA
      • Sensitive-area involvement: Atopic dermatitis involvement is estimated at less than 10% of the body surface area and affects the face, eyes or eyelids, skin folds, and/or genitalia according to the prescribing physician.<10% BSA
    • Topical treatment history: Documentation shows inadequate response, serious side effects, or contraindication to two of the following: topical corticosteroids or a preferred/formulary topical calcineurin inhibitor, tacrolimus or pimecrolimus.2 therapies
    • Additional treatment history: Documentation shows inadequate response, serious side effects, or contraindication to one of the following: Eucrisa (crisaborole), Opzelura (ruxolitinib), Vtama (tapinarof), or Zoryve (roflumilast).1 therapy
    • Baseline disease assessment: The prescriber documents baseline disease activity, such as erythema, induration/papulation/edema, excoriations, lichenification, pruritus, affected body surface area, or topical treatment requirement.
    • Non-preferred product requirement: If Ebglyss is non-formulary or non-preferred, documentation shows trial and failure of or serious side effects to a majority of preferred formulary or PDL alternatives for the diagnosis.Majority, not more than 3 alternatives

      Submit the medications tried, trial dates, and reasons for treatment failure.

    Continuation Therapy

    Continuation of therapy is covered when ALL of the following are met.

    Continuation therapy

    • Adherence is at least 85% of the time, or adherence is below 85% because surgery or treatment of an infection caused temporary discontinuation.≥85% adherence

      Verified by the prescriber or member medication fill history.

    • Safety: The prescriber attests to, or clinical review finds, no evidence of intolerable adverse effects or drug toxicity.
    • Positive clinical response: Documentation demonstrates positive clinical response through low disease activity and/or improvement in signs and symptoms, including improvement in erythema, induration/papulation/edema, excoriations, lichenification, pruritus, affected body surface area, or reduced need for other topical or systemic therapies.

    Ebglyss will not be covered when used concurrently with or in combination with a TNF inhibitor, biologic response modifier, other biologic DMARD, Janus kinase inhibitor, or phosphodiesterase 4 inhibitor.

    No compendial approved off-label uses are identified for Ebglyss.

    Uses of Ebglyss other than the covered indication for moderate-to-severe atopic dermatitis are considered experimental or investigational and follow Molina's Off-Label policy.

    A history of serious hypersensitivity to lebrikizumab-lbkz or any excipient in Ebglyss is a contraindication to treatment.

    Live vaccines should be avoided during Ebglyss treatment.

    Coding and Clinical Thresholds

    HCPCS CodeHCPCS
    NA
    Extensive Body Surface Area Involvement
    ThresholdAt least 10% of body surface area (BSA) affected by atopic dermatitis
    AssessmentBSA involvement must be estimated by the prescribing physician
    PathwayQualifies as the extensive disease-extent pathway for moderate-to-severe atopic dermatitis
    Limited Body Surface Area with Sensitive-Area Involvement
    ThresholdLess than 10% of body surface area (BSA) affected
    Sensitive areasInvolvement affects the face, eyes or eyelids, skin folds, and/or genitalia

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization and Duration

    Prior authorization is required for Ebglyss coverage. Approval is limited to the applicable authorization period and requires continued compliance with coverage criteria for reauthorization.

    • Initial authorization: 6 months.
    • Continuation authorization: 12 months.
    Prior Authorization

    Illinois Authorization Duration

    For an Illinois Marketplace member receiving Ebglyss for a chronic or long-term condition, a recurring-service or maintenance-medication prior authorization remains valid for the lesser of 12 months from approval or the length of treatment determined by the treating professional.

    • This provision does not require coverage of care or services otherwise excluded from the member’s benefits.
    • The statutory exception does not apply to benzodiazepines or Schedule II narcotics, such as opioids.

    Clinical Background

    Atopic dermatitis is a chronic inflammatory skin disease that can range from moderate to severe. Disease may not be adequately controlled with topical prescription therapies, or topical therapies may not be advisable. Ebglyss is indicated for adults and pediatric patients aged 12 years and older who weigh at least 40 kg and have moderate-to-severe atopic dermatitis; it may be used with or without topical corticosteroids.

    Definitions and Clinical Measures

    Body Surface Area (BSA)
    DefinitionThe proportion of total body surface area affected by atopic dermatitis
    UseUsed to assess the extent of atopic dermatitis involvement
    Assessment sourceEstimated by the prescribing physician
    Positive Clinical Response
    DefinitionClinical improvement shown by low disease activity and/or improvement in signs and symptoms
    Signs and symptomsMay include improvement in erythema, induration/papulation/edema, excoriations, lichenification, pruritus, or affected BSA
    Treatment effect

    Ebglyss Initial Therapy

    Ebglyss Initial Therapy

    Initial Ebglyss therapy is covered when ALL of the following are met.

    Ebglyss initial therapy

    • Diagnosis: The member has a documented diagnosis of moderate-to-severe chronic atopic dermatitis (eczema).
    • No prohibited combination therapy: The member is not receiving concurrent treatment with, and Ebglyss will not be used in combination with, a TNF inhibitor, biologic response modifier, other biologic DMARD, Janus kinase inhibitor, or phosphodiesterase 4 inhibitor.

      Verification may be by prescriber attestation, member medication fill history, or submitted documentation.

    • Disease extent

      • Extensive involvement:

    Ebglyss Continuation Therapy

    Ebglyss Continuation Therapy

    Continuation of Ebglyss therapy requires ALL of the following.

    Ebglyss continuation requirements

    • Adherence is at least 85% of the time, or adherence is less than 85% because surgery or treatment of an infection caused temporary discontinuation.≥85% adherence

      Verified by the prescriber or member medication fill history.

    • Safety: The prescriber attests to, or clinical review finds, no evidence of intolerable adverse effects or drug toxicity.
    • Positive clinical response: Documentation demonstrates positive clinical response through low disease activity and/or improvement in signs and symptoms, including improvement in erythema, induration/papulation/edema, excoriations, lichenification, pruritus, affected body surface area, or reduced need for other topical or systemic therapies.

    Step-Therapy Requirements

    StepRequired therapy historyDocumentation required
    1Failure, intolerance, or contraindication to two topical therapies: topical corticosteroids or a preferred/formulary topical calcineurin inhibitor (tacrolimus or pimecrolimus).Document inadequate response, serious side effects, or contraindication to each of the two therapies.
    StepProduct preference requirementDocumentation required
    2For non-formulary or non-preferred Ebglyss, trial and failure of or serious side effects to a majority of preferred formulary or PDL alternatives for the diagnosis; no more than three alternatives.Submit the medication(s) tried, trial dates, and reasons for treatment failure.

    Dosing and Quantity Limits

    Ebglyss (lebrikizumab) Dosing
    Loading dose500 mg at Week 0 and Week 2
    Induction dose250 mg every two weeks until Week 16 or later, when adequate clinical response is achieved
    Maintenance options250 mg every four weeks or 250 mg every eight weeks

    Site of Care and Administration

    Note

    Use pharmacy benefit and home administration

    Injectable Ebglyss is recommended for pharmacy benefit coverage and patient self-administration.

    Policy Summary
    PayerMolina Healthcare
    PolicyEbglyss (lebrikizumab) Coverage Criteria
    Policy CodePolicy C29044-A
    Change TypeModified
    Effective DateSep 24, 2026
    Next Review DateApr 1, 2027
    Key ActionSubmit prior authorization documentation for Ebglyss, including clinical criteria, treatment history, and qualified prescriber information.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsAuthorization, Documentation, and Denial RisksClinical BackgroundDefinitions and Clinical MeasuresEbglyss Initial TherapyEbglyss Continuation TherapyStep-Therapy RequirementsDosing and Quantity LimitsSite of Care and Administration
    Assessment
    BSA involvement and affected sensitive areas must be estimated by the prescribing physician
    Minimum Age
    Minimum age12 years of age and older
    Eligible populationAdults and pediatric patients aged 12 years and older with moderate-to-severe atopic dermatitis
    Treatment contextDisease must not be adequately controlled with topical prescription therapies or those therapies must not be advisable
    Minimum Weight for FDA-Approved Use
    Minimum weightAt least 40 kg
    PopulationAdults and pediatric patients with moderate-to-severe atopic dermatitis
    FDA-approved useDisease is not adequately controlled with topical prescription therapies or those therapies are not advisable
    Continuation Adherence
    Required adherenceAt least 85% of the time
    Temporary interruption exceptionAdherence below 85% may qualify when surgery or treatment of an infection caused temporary discontinuation
    VerificationAdherence is verified by the prescriber or the member's medication fill history
    Prior Authorization

    Illinois Medical Exception

    For an Illinois Marketplace member, an off-formulary exception request must not be denied when a qualifying medical exception is documented. If granted, coverage must be authorized for the prescribed covered drug up to the covered quantity.

    • The formulary drug is contraindicated.
    • The member tried the formulary drug under the current or a previous plan and the prescriber submits evidence of failure or intolerance.
    • The member is stable on the prescribed drug selected by the treating provider under the current or a previous plan.

    Unsupported block type: documentation

    Step Therapy

    Document Required Topical Therapy Trials

    Document inadequate response, serious side effects, or a contraindication to two required topical therapies before requesting Ebglyss.

    • Topical corticosteroids.
    • A preferred or formulary topical calcineurin inhibitor: tacrolimus or pimecrolimus.
    Step Therapy

    Document Additional Nonsteroidal Therapy Trial

    Document an inadequate response, serious side effects, or a contraindication to one required nonsteroidal therapy before requesting Ebglyss.

    • Eucrisa (crisaborole).
    • Opzelura (ruxolitinib).
    • Vtama (tapinarof).
    • Zoryve (roflumilast).
    Documentation Required

    General Medical Documentation

    Make patient and provider records available when requested to support the coverage determination, medical necessity, noninvestigational status, and benefit eligibility. Molina may request additional information and may deny reimbursement or take other action when documentation is insufficient or billing practices are inappropriate or excessive.

    • Patient records and test results.
    • Credentials of the provider ordering or performing the drug or service.
    • Member-specific dosing data, including weight or body-surface area, when applicable.
    • Additional case-specific supporting documentation requested for review.
    Documentation Required

    Initial Clinical Documentation

    For the initial request, submit documentation supporting the diagnosis, disease extent, treatment history, and baseline disease activity assessment.

    • Documented moderate-to-severe chronic atopic dermatitis (eczema).
    • Estimated BSA involvement of at least 10%, or less than 10% when affecting the face, eyes or eyelids, skin folds, and/or genitalia.
    • Prior treatment trials and outcomes, including required topical and nonsteroidal therapies.
    • Baseline findings such as erythema, induration/papulation/edema, excoriations, lichenification, pruritus, BSA affected, and topical-therapy requirements.
    Step Therapy

    Formulary Exception Documentation

    When Ebglyss is non-formulary or non-preferred, document trial and failure of or serious side effects to a majority of the preferred formulary or PDL alternatives for the diagnosis.

    • Submit the medication or medications tried.
    • Include the dates of each trial.
    • Explain the reason for treatment failure or intolerance.
    • The required majority is not more than three preferred alternatives.
    Documentation Required

    Reauthorization Documentation

    For reauthorization, document adherence, any qualifying temporary interruption, tolerability, and positive clinical response.

    • Adherence of at least 85%, or adherence below 85% because of surgery or infection requiring temporary discontinuation.
    • No intolerable adverse effects or drug toxicity.
    • Low disease activity and/or improvement in signs and symptoms.
    Documentation Required

    Qualified Prescriber Documentation

    Ebglyss must be prescribed by, or in consultation with, a board-certified allergist, immunologist, or dermatologist. When consultation is used, submit the consultation notes with both the initial request and reauthorization requests.

    Documentation Required

    Evidence of Formulary Failure or Intolerance

    For an Illinois medical-exception request, submit supporting evidence that the formulary drug was contraindicated, failed, or was not tolerated, or that the member is stable on the requested drug.

    • Include evidence of formulary-drug failure or intolerance when the member previously tried the drug under the current or a prior plan.
    • Document the relevant contraindication when applicable.
    • Document stability on the requested drug when that is the basis for the exception.
    Documentation Required

    Medical-Exception Support

    Support an Illinois exception request with clinical documentation establishing the applicable contraindication or the member’s stability on the requested medication.

    • A contraindicated formulary drug supports the exception.
    • Stability on a provider-selected prescription drug under a current or previous plan supports the exception.
    Denial Risk

    Insufficient Supporting Documentation

    Molina may deny reimbursement or take other appropriate action when supporting documentation does not establish medical necessity, noninvestigational status, benefit eligibility, or appropriate billing.

    • Submit records and test results sufficient to support the determination.
    • Provide requested provider credentials and other case-specific documentation.
    Denial Risk

    Clinical Criteria Not Met

    Coverage may be denied when the requested use or clinical documentation does not meet the policy criteria for diagnosis, disease severity, treatment history, or baseline assessment.

    • Moderate-to-severe chronic atopic dermatitis must be documented.
    • Applicable BSA or sensitive-area involvement must be documented.
    • Required topical and nonsteroidal therapy trials, failures, intolerances, or contraindications must be documented.
    • A baseline disease-activity assessment must be provided.
    Denial Risk

    Prohibited Concurrent Therapy

    Do not use Ebglyss concurrently with, or in combination with, a TNF inhibitor, biologic response modifier, other biologic DMARD, Janus kinase inhibitor, or phosphodiesterase 4 inhibitor.

    • The absence of prohibited concurrent therapy must be verified by prescriber attestation, medication fill history, or submitted documentation.
    Step Therapy

    Preferred Alternative Requirement

    For a non-formulary or non-preferred request, the required preferred formulary or PDL alternatives must be tried and shown to have failed or caused serious side effects, unless an applicable exception is documented.

    • Document trials of a majority of the preferred alternatives, not more than three.
    • Include medications tried, trial dates, and reasons for failure or intolerance.
    Denial Risk

    Continuation Criteria Not Met

    Continuation coverage may be denied when the member does not meet the adherence, tolerability, and positive-response requirements.

    • Adherence must be at least 85%, unless a qualifying surgery- or infection-related interruption occurred.
    • There must be no intolerable adverse effects or drug toxicity.
    • The record must show positive clinical response, such as low disease activity or improved signs and symptoms.
    Denial Risk

    Unapproved or Off-Label Use

    Uses outside the covered population or otherwise outside the policy criteria are considered experimental or investigational and follow Molina’s Off-Label policy.

    • The covered population includes members 12 years of age and older with the policy-defined indication.
    • Do not request coverage for unapproved or off-label use without applicable policy support.
    Denial Risk

    Hypersensitivity or Unresolved Helminth Infection

    Do not initiate Ebglyss in a patient with prior serious hypersensitivity to lebrikizumab or an excipient. Discontinue treatment for a serious hypersensitivity reaction, and address helminth infection before initiation or during treatment as required.

    • Hypersensitivity reactions may include angioedema and urticaria; discontinue Ebglyss if a serious reaction occurs.
    • Treat a pre-existing helminth infection before initiating Ebglyss.
    • If helminth infection develops during treatment and does not respond to standard antihelminth therapy, discontinue Ebglyss until the infection resolves.
    Denial Risk

    Avoid Live Vaccines During Treatment

    Avoid live vaccines during Ebglyss treatment.

    • Complete age-appropriate vaccinations before treatment when possible.
    Billing Rule

    Improper Billing or Noncovered Benefit

    Submit claims using standard coding and billing practices and confirm that Ebglyss is a covered benefit. Molina may reject or deny an improperly billed or noncovered claim and recover payments already made.

    • Verify benefit coverage before billing.
    • Correct billing or coverage issues may be subject to payment recovery.
    May include reduced need for topical or systemic therapies
    EASI-75
    DefinitionAt least a 75% improvement in the Eczema Area and Severity Index
    AbbreviationEASI-75
    Clinical useUsed as an efficacy measure for treatment response in the cited Ebglyss trials
    Investigator's Global Assessment (IGA)
    DefinitionA clinical assessment score used to evaluate atopic dermatitis severity
    Successful-treatment thresholdA score of 0 or 1
    Clinical useUsed as an efficacy measure in the cited Ebglyss trials
    Atopic dermatitis involvement is estimated at at least 10% of the body surface area according to the prescribing physician.
    ≥10% BSA
  1. Sensitive-area involvement: Atopic dermatitis involvement is estimated at less than 10% of the body surface area and affects the face, eyes or eyelids, skin folds, and/or genitalia according to the prescribing physician.<10% BSA
  2. Topical treatment history: Documentation shows inadequate response, serious side effects, or contraindication to two of the following: topical corticosteroids or a preferred/formulary topical calcineurin inhibitor, tacrolimus or pimecrolimus.2 therapies
  3. Additional treatment history: Documentation shows inadequate response, serious side effects, or contraindication to one of the following: Eucrisa (crisaborole), Opzelura (ruxolitinib), Vtama (tapinarof), or Zoryve (roflumilast).1 therapy
  4. Baseline disease assessment: The prescriber documents baseline disease activity, such as erythema, induration/papulation/edema, excoriations, lichenification, pruritus, affected body surface area, or topical treatment requirement.
  5. Formulary requirement: If Ebglyss is non-formulary or non-preferred, documentation shows trial and failure of or serious side effects to a majority of preferred formulary or PDL alternatives for the diagnosis.Majority, not more than 3 alternatives

    Submit the medications tried, trial dates, and reasons for treatment failure.